Skip to main content

DiaMedica Therapeutics Inc. (DMAC)

NASDAQ: DMAC · IEX Real-Time Price · USD
4.18 0.13 (3.21%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap78.53M
Revenue (ttm)n/a
Net Income (ttm)-14.29M
Shares Out18.79M
EPS (ttm)-0.78
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume263,596
Open4.09
Previous Close4.05
Day's Range3.95 - 4.24
52-Week Range3.00 - 10.88
Beta2.44
AnalystsStrong Buy
Price Target22.50 (+438.3%)
Est. Earnings DateNov 3, 2021

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeu...

IndustryBiotechnology
Founded2000
Employees10
Stock ExchangeNASDAQ
Ticker SymbolDMAC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is 22.50, which is an increase of 438.28% from the latest price.

Price Target
$22.50
(438.28% upside)
Analyst Consensus: Strong Buy

News

DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurren...

4 days ago - Zacks Investment Research

DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

5 days ago - Business Wire

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

1 week ago - Business Wire

4 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:CLRODRTTTRUE
1 month ago - Benzinga

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

1 month ago - Business Wire

DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

1 month ago - Business Wire

DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

1 month ago - Business Wire

New Strong Sell Stocks for July 21st

CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.

Other symbols:CLOVCNOHCATIMAX
1 month ago - Zacks Investment Research

DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

2 months ago - Business Wire

Moving Average Crossover Alert: DiaMedica Therapeutics (DMAC)

DiaMedica Therapeutics (DMAC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

2 months ago - Zacks Investment Research

DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients

DiaMedica Therapeutics Inc (NASDAQ: DMAC) has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD).  The trial is designed to evaluate the effect of D...

2 months ago - Benzinga

DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal di...

2 months ago - Business Wire

Is the Options Market Predicting a Spike in DiaMedica (DMAC) Stock?

Investors need to pay close attention to DiaMedica (DMAC) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke

The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or ...

4 months ago - Benzinga

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for ...

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseases...

4 months ago - Business Wire

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

4 months ago - Business Wire

DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

4 months ago - Business Wire

DiaMedica Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

4 months ago - Business Wire

New Strong Sell Stocks for April 20th

ATTO, DMAC, DG, GEL, and IAG have been added to the Zacks Rank #5 (Strong Sell) List on April 20, 2021

Other symbols:ATTODGGELIAG
4 months ago - Zacks Investment Research

DiaMedica Therapeutics to Present Research at the National Kidney Foundation's 2021 Spring Clinical Meetings

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

5 months ago - Business Wire

DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

6 months ago - Business Wire

DiaMedica Therapeutics to Present Research at International Stroke Virtual Conference

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel recombinant proteins in the treatments for neurological and kidney d...

6 months ago - Business Wire

DiaMedica Therapeutics Hosting Key Opinion Leader Webinar on DM199 for Treatment of Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced tha...

6 months ago - Business Wire

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

6 months ago - Business Wire

DiaMedica Therapeutics to Report Fourth Quarter 2020 Financials and Provide a Business Update March 11, 2021

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases...

6 months ago - Business Wire